| Symbol | AGIO |
|---|---|
| Name | AGIOS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 88 SIDNEY STREET, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 649-8600 |
| Fax | — |
| — | |
| Website | https://www.agios.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The companys primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. Additional info from NASDAQ: |
2026-04-06 20:10
Gheuens Sarah 🟡 adjusted position in 2.9K shares (1 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.71 Transaction Date: Apr 02, 2026 | Filing ID: 000065
Read more
2026-04-06 20:08
Jones Cecilia 🟡 adjusted position in 3.1K shares (1 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.71 Transaction Date: Apr 02, 2026 | Filing ID: 000063
Read more
2026-04-06 20:07
Milanova Tsveta 🟡 adjusted position in 3.3K shares (1 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.71 Transaction Date: Apr 02, 2026 | Filing ID: 000061
Read more
2026-04-06 20:05
Viswanadhan Krishnan 🟡 adjusted position in 3.0K shares (1 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.71 Transaction Date: Apr 02, 2026 | Filing ID: 000059
Read more
2026-04-06 20:04
Director Goff Brian 🟡 adjusted position in 19.1K shares (2 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.71 Transaction Date: Apr 02, 2026 | Filing ID: 000057
Read more
2026-04-06 11:00
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Read more
2026-04-02 20:09
📋 Goff Brian (Officer) plans to sell 19K shares of AGIOS PHARMACEUTICALS, INC. (at $34.19 each, total $652K) Filed: Apr 02, 2026 | ID: 000055
Read more
2026-04-02 20:07
📋 Jones Cecilia (Officer) plans to sell 3K shares of AGIOS PHARMACEUTICALS, INC. (at $34.19 each, total $107K) Filed: Apr 02, 2026 | ID: 000054
Read more
2026-04-02 20:05
📋 Viswanadhan Krishnan (Officer) plans to sell 3K shares of AGIOS PHARMACEUTICALS, INC. (at $34.19 each, total $101K) Filed: Apr 02, 2026 | ID: 000053
Read more
2026-04-02 20:04
📋 Milanova Tsveta (Officer) plans to sell 3K shares of AGIOS PHARMACEUTICALS, INC. (at $34.19 each, total $112K) Filed: Apr 02, 2026 | ID: 000052
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03523338 | An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-… | — | Prostatic Neoplasms | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Muta… | — | Acute Myeloid Leukemia | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07506863 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat … | Phase3 | Transfusion-dependent Alpha-Thalassemia | Not_Yet_Recruiting | 2026-09-01 | 2032-06-01 | ClinicalTrials.gov |
| NCT07517133 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat … | Phase3 | Non-Transfusion-dependent Alpha-Thalassemia | Not_Yet_Recruiting | 2026-09-01 | 2032-03-01 | ClinicalTrials.gov |
| NCT07241234 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… | Phase1 | Phenylketonuria | Not_Yet_Recruiting | 2026-03-01 | 2028-01-17 | ClinicalTrials.gov |
| NCT06286046 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | Phase2 | Sickle Cell Disease | Withdrawn | 2026-03-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorb… | Phase1 | Healthy Participants | Recruiting | 2025-07-07 | 2026-08-31 | ClinicalTrials.gov |
| NCT07055243 | To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of t… | Phase2 | Anemia | Recruiting | 2025-06-26 | 2027-06-30 | ClinicalTrials.gov |
| NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participant… | Phase2 | Sickle Cell Disease | Active_Not_Recruiting | 2025-05-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT06911424 | Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis | Phase3 | Bacterial Conjunctivitis | Recruiting | 2025-03-21 | 2026-03-23 | ClinicalTrials.gov |
| NCT06955988 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of… | Phase1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | 2025-03-04 | 2027-06-01 | ClinicalTrials.gov |
| NCT06745271 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From t… | Phase1 | Healthy Participants | Completed | 2024-12-20 | 2025-02-21 | ClinicalTrials.gov |
| NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NS… | Phase3 | EGFR | Recruiting | 2024-11-19 | 2028-07-01 | ClinicalTrials.gov |
| NCT06648824 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants | Phase1 | Healthy Participants | Completed | 2024-10-17 | 2024-12-03 | ClinicalTrials.gov |
| NCT06970639 | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versu… | Phase3 | NSCLC Patients With Brain Metastasis | Recruiting | 2024-09-26 | 2029-09-01 | ClinicalTrials.gov |
| NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment o… | Phase3 | Advanced Non-squamous Non-small-cell Lung Cancer | Recruiting | 2024-08-07 | 2027-02-28 | ClinicalTrials.gov |
| NCT06286033 | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 | Phase1 | Healthy Volunteers | Completed | 2024-02-20 | 2025-10-09 | ClinicalTrials.gov |
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancre… | Phase2 | KRAS P.G12C | Recruiting | 2023-10-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT05920941 | Mass Balance Study of [14C]JAB-21822 | Phase1 | Mass Balance Study in Healthy Subjects | Completed | 2023-07-08 | 2023-08-09 | ClinicalTrials.gov |
| NCT05777993 | A Study to Provide Continued Access to Mitapivat for Participants Who Previousl… | Phase4 | Pyruvate Kinase Deficiency | Enrolling_By_Invitation | 2023-07-06 | 2029-08-01 | ClinicalTrials.gov |
| NCT05875493 | A Food Effect Study of JAB-21822 in Healthy Subjects | Phase1 | Food Effect in Healthy Participants | Completed | 2023-05-12 | 2023-06-14 | ClinicalTrials.gov |
| NCT05610657 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impa… | Phase1 | Moderate Hepatic Impairment | Completed | 2023-01-10 | 2023-07-21 | ClinicalTrials.gov |
| NCT05387798 | A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients Wit… | Phase3 | Prader-Willi Syndrome | Withdrawn | 2023-01-01 | 2025-08-01 | ClinicalTrials.gov |
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Mye… | Phase2 | Myelodysplastic Syndromes | Active_Not_Recruiting | 2022-11-07 | 2029-03-01 | ClinicalTrials.gov |
| NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metas… | Phase2 | NSCLC | Active_Not_Recruiting | 2022-09-27 | 2026-12-01 | ClinicalTrials.gov |
| NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participa… | Phase3 | Pediatric Pyruvate Kinase Deficiency | Active_Not_Recruiting | 2022-06-08 | 2029-06-01 | ClinicalTrials.gov |
| NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participa… | Phase3 | Pediatric Pyruvate Kinase Deficiency | Active_Not_Recruiting | 2022-06-06 | 2030-01-01 | ClinicalTrials.gov |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tum… | Phase1 | KRAS P.G12C | Recruiting | 2022-04-14 | 2026-03-01 | ClinicalTrials.gov |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other… | Phase1 | Advanced Colorectal Cancer | Active_Not_Recruiting | 2022-02-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participant… | Phase2 | Sickle Cell Disease | Active_Not_Recruiting | 2022-02-11 | 2030-02-01 | ClinicalTrials.gov |
| NCT04902833 | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | — | Pyruvate Kinase Deficiency | Active_Not_Recruiting | 2022-02-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With No… | Phase3 | Non-Transfusion-dependent Alpha-Thalassemia | Active_Not_Recruiting | 2021-12-20 | 2028-12-01 | ClinicalTrials.gov |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Local… | Phase2 | Non-Small-Cell Lung Cancer | Unknown | 2021-12-09 | 2024-12-31 | ClinicalTrials.gov |
| NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Tr… | Phase3 | Transfusion-dependent Alpha-Thalassemia | Active_Not_Recruiting | 2021-11-30 | 2029-06-01 | ClinicalTrials.gov |
| NCT05374278 | First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tr… | Phase1 | Alzheimer Disease | Recruiting | 2021-11-02 | 2027-05-31 | ClinicalTrials.gov |
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients W… | Phase2 | Non-Small-Cell Lung Cancer | Unknown | 2021-10-12 | 2023-11-30 | ClinicalTrials.gov |
| NCT04056910 | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | Phase2 | Advanced Solid Tumor | Completed | 2021-09-20 | 2023-11-13 | ClinicalTrials.gov |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EG… | Phase2 | Lung Adenocarcinoma | Not_Yet_Recruiting | 2021-08-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRA… | Phase1 | NSCLC | Active_Not_Recruiting | 2021-07-26 | 2026-12-01 | ClinicalTrials.gov |
| NCT04964323 | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported … | — | Pyruvate Kinase Deficiency | Terminated | 2021-07-02 | 2023-06-30 | ClinicalTrials.gov |
| NCT04995315 | Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG… | — | Pyruvate Kinase Deficiency | Completed | 2021-07-02 | 2023-09-22 | ClinicalTrials.gov |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPN… | Phase2 | Malignant Peripheral Nerve Sheath Tumors (MPNST) | Recruiting | 2021-04-29 | 2027-04-01 | ClinicalTrials.gov |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | Phase1 | Solid Tumor | Completed | 2021-03-23 | 2023-12-19 | ClinicalTrials.gov |
| NCT04696393 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet F… | Phase1 | Healthy Volunteers | Completed | 2021-01-06 | 2021-03-19 | ClinicalTrials.gov |
| NCT04565678 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated… | Phase1 | Healthy Volunteers | Completed | 2020-09-21 | 2020-12-03 | ClinicalTrials.gov |
| NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | Phase1 | NSCLC | Active_Not_Recruiting | 2020-08-10 | 2026-02-28 | ClinicalTrials.gov |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | Phase1 | Non-small Cell Lung Cancer | Completed | 2020-07-14 | 2022-06-17 | ClinicalTrials.gov |
| NCT04536792 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Volunteers | Completed | 2020-07-10 | 2023-12-19 | ClinicalTrials.gov |
| NCT04472832 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat… | Phase1 | Healthy Volunteers | Completed | 2020-06-17 | 2020-11-23 | ClinicalTrials.gov |
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | Phase2 | Chondrosarcoma | Active_Not_Recruiting | 2020-03-04 | 2027-03-01 | ClinicalTrials.gov |
| NCT04145128 | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants | Phase1 | Healthy Volunteers | Completed | 2019-10-02 | 2019-12-18 | ClinicalTrials.gov |
| NCT04128787 | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and … | Phase1 | Healthy Volunteers | Completed | 2019-09-30 | 2019-12-18 | ClinicalTrials.gov |
| NCT04015687 | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Do… | Phase1 | Healthy Participants | Completed | 2019-07-15 | 2019-10-09 | ClinicalTrials.gov |
| NCT04000165 | A Dose-Finding Study of AG-348 in Sickle Cell Disease | Early_Phase1 | Sickle Cell Disease | Completed | 2019-07-11 | 2021-06-21 | ClinicalTrials.gov |
| NCT03991312 | Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on … | Phase1 | Healthy Volunteers | Completed | 2019-06-20 | 2019-09-10 | ClinicalTrials.gov |
| NCT03787992 | Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metas… | Phase3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | Active_Not_Recruiting | 2019-05-30 | 2026-03-01 | ClinicalTrials.gov |
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | Phase1 | Lymphoma | Terminated | 2019-05-24 | 2020-06-17 | ClinicalTrials.gov |
| NCT03960502 | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Follo… | Phase1 | Healthy Male Participants | Completed | 2019-05-16 | 2019-09-07 | ClinicalTrials.gov |
| NCT03941340 | Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST… | Phase1 | Healthy Male Volunteers | Completed | 2019-04-08 | 2019-09-06 | ClinicalTrials.gov |
| NCT03853798 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency… | Phase3 | Pyruvate Kinase Deficiency | Completed | 2019-03-21 | 2024-07-03 | ClinicalTrials.gov |
| NCT03692052 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynami… | Phase2 | Thalassemia | Active_Not_Recruiting | 2019-03-20 | 2030-09-30 | ClinicalTrials.gov |
| NCT03926182 | Study to Determine the Effect of Food on the Blood Levels of AST2818 Following … | Phase1 | Healthy Male Volunteers | Completed | 2019-02-19 | 2019-04-03 | ClinicalTrials.gov |
| NCT03564821 | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid… | Phase1 | IDH1 Mutation Myeloid Neoplasms | Completed | 2019-01-16 | 2023-06-06 | ClinicalTrials.gov |
| NCT04026178 | Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy | Phase4 | Generalized Lipodystrophy | Completed | 2018-11-14 | 2024-10-31 | ClinicalTrials.gov |
| NCT03548220 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused A… | Phase3 | Pyruvate Kinase Deficiency | Completed | 2018-08-09 | 2020-10-09 | ClinicalTrials.gov |
| NCT03559699 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Ad… | Phase3 | Pyruvate Kinase Deficiency | Completed | 2018-06-26 | 2020-11-12 | ClinicalTrials.gov |
| NCT03452592 | Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small C… | Phase2 | Advanced NSCLC Patients With T790M | Terminated | 2018-04-30 | 2024-03-14 | ClinicalTrials.gov |
| NCT03481738 | Pyruvate Kinase Deficiency Global Longitudinal Registry | — | Pyruvate Kinase Deficiency | Active_Not_Recruiting | 2018-04-23 | 2027-05-31 | ClinicalTrials.gov |
| NCT03361358 | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma | — | Advanced Solid Tumors | Completed | 2018-03-01 | 2019-09-30 | ClinicalTrials.gov |
| NCT03397329 | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet … | Phase1 | Healthy Volunteers | Completed | 2017-10-03 | 2017-11-13 | ClinicalTrials.gov |
| NCT03282513 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impair… | Phase1 | Hepatic Impairment | Completed | 2017-09-26 | 2018-03-31 | ClinicalTrials.gov |
| NCT03250598 | Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Hea… | Phase1 | Healthy | Completed | 2017-08-09 | 2017-10-09 | ClinicalTrials.gov |
| NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Na | Advanced NSCLC | Terminated | 2017-06-01 | 2024-01-08 | ClinicalTrials.gov |
| NCT03071770 | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects | Phase1 | Healthy | Completed | 2017-03-31 | 2017-09-06 | ClinicalTrials.gov |
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib i… | Phase1 | NSCLC | Terminated | 2016-12-30 | 2023-08-01 | ClinicalTrials.gov |
| NCT02742129 | Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF | Phase2 | Heart Failure | Completed | 2016-08-10 | 2017-12-27 | ClinicalTrials.gov |
| NCT02831972 | Drug-Drug Interaction Study of AG120 in Healthy Subjects | Phase1 | Healthy | Completed | 2016-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02765841 | Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homoz… | Phase3 | Homozygous Familial Hypercholesterolemia | Withdrawn | 2016-05-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02592317 | A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmac… | Phase1 | Prostatic Neoplasms, Castration-Resistant | Active_Not_Recruiting | 2016-02-12 | 2027-12-31 | ClinicalTrials.gov |
| NCT02578797 | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | Phase1 | Castration-Resistant Prostate Cancer | Completed | 2015-12-18 | 2022-10-13 | ClinicalTrials.gov |
| NCT02630927 | A Safety and Tolerability Study of AG-519 in Healthy Subjects | Phase1 | Anemia | Terminated | 2015-12-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02653417 | Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women Wi… | Phase2 | Vasomotor Symptoms | Terminated | 2015-12-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therap… | Phase3 | Prostate Cancer | Active_Not_Recruiting | 2015-11-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT02531516 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostat… | Phase3 | Prostatic Neoplasms | Active_Not_Recruiting | 2015-11-19 | 2028-12-29 | ClinicalTrials.gov |
| NCT02579707 | Food Effect Study of AG120 in Healthy Subjects | Phase1 | Healthy | Completed | 2015-10-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02524717 | A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With M… | Phase1 | Hepatic Impairment | Completed | 2015-08-13 | 2017-02-09 | ClinicalTrials.gov |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malig… | Phase1 | Acute Myeloid Leukemia (AML) | Completed | 2015-08-07 | 2018-03-21 | ClinicalTrials.gov |
| NCT02476916 | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency | Phase2 | Pyruvate Kinase Deficiency | Completed | 2015-06-26 | 2025-04-02 | ClinicalTrials.gov |
| NCT02399852 | Effects of Lomitapide on Carotid and Aortic Atherosclerosis | — | Homozygous Familial Hypercholesterolemia | Withdrawn | 2015-06-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02489513 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02257736 | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With … | Phase3 | Prostatic Neoplasms | Active_Not_Recruiting | 2014-11-26 | 2027-12-31 | ClinicalTrials.gov |
| NCT02262078 | Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction | Phase2 | Heart Failure | Completed | 2014-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02230033 | Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and J… | Phase1 | Healthy | Completed | 2014-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02218346 | Food Effect Study of AG-221 in Healthy Male Subjects | Phase1 | Healthy Volunteers | Completed | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With … | Phase1 | Prostatic Neoplasms | Active_Not_Recruiting | 2014-07-09 | 2027-12-31 | ClinicalTrials.gov |
| NCT02160756 | Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-5… | Phase1 | Healthy | Completed | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02149966 | A Phase I Study of AG-348 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2014-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02173158 | Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent … | Phase3 | Familial Hypercholesterolemia - Homozygous | Completed | 2014-04-02 | 2015-12-17 | ClinicalTrials.gov |
| NCT02108106 | A Phase I Study of AG-348 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2014-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02080468 | Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics o… | Phase1 | Healthy | Completed | 2014-02-19 | 2014-04-24 | ClinicalTrials.gov |
| NCT02080455 | Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in He… | Phase1 | Effect of Atorvastatin on the Pharmacokinetics of Lomitapide | Completed | 2014-01-27 | 2014-03-07 | ClinicalTrials.gov |
| NCT02053480 | Pyruvate Kinase Deficiency Natural History Study | — | Pyruvate Kinase Deficiency | Completed | 2013-12-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02031666 | A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of… | Phase1 | Healthy | Completed | 2013-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02044419 | A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled | Phase1 | Healthy | Completed | 2013-10-30 | 2013-12-23 | ClinicalTrials.gov |
| NCT01946204 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistan… | Phase3 | Prostatic Neoplasms | Active_Not_Recruiting | 2013-10-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT01915498 | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Mali… | Phase1 | Hematologic Neoplasms | Completed | 2013-08-27 | 2023-10-31 | ClinicalTrials.gov |
| NCT01915771 | Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitap… | Phase1 | Intra-subject Variability of Pharmacokinetics | Completed | 2013-07-29 | 2013-08-23 | ClinicalTrials.gov |
| NCT01790126 | The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men Wit… | Phase2 | Prostate Cancer | Completed | 2013-03-04 | 2019-03-01 | ClinicalTrials.gov |
| NCT01792687 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of … | Phase1 | Prostate Cancer | Completed | 2013-02-05 | 2024-02-13 | ClinicalTrials.gov |
| NCT01760187 | Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese an… | Phase1 | Healthy Volunteer | Completed | 2012-11-07 | 2013-06-03 | ClinicalTrials.gov |
| NCT01409122 | Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution i… | Phase1 | Pulmonary Hypertension | Completed | 2011-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in … | Phase1 | Prostate Cancer | Completed | 2010-07-26 | 2025-07-22 | ClinicalTrials.gov |
| NCT00943306 | Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial H… | Phase3 | Familial Hypercholesterolemia | Completed | 2009-10-29 | 2014-12-01 | ClinicalTrials.gov |
| NCT00875420 | A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Sympto… | Phase2 | Hot Flashes | Completed | 2009-03-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00814645 | Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation… | Phase1 | Pulmonary Arterial Hypertension | Completed | 2008-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00690443 | Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monot… | Phase2 | Hypercholesterolemia | Completed | 2008-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00559962 | Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS | Phase2 | Hyperlipidemia | Completed | 2007-10-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00405067 | The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Mono… | Phase2 | Hypercholesterolemia | Completed | 2006-05-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00359281 | Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents | Phase2 | Healthy | Completed | 2006-03-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT01556906 | Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhi… | Phase2 | Homozygous Familial Hypercholesterolemia | Completed | 2003-06-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT02778646 | Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry | — | Familial Hypercholesterolemia | Completed | 2003-01-01 | 2014-12-01 | ClinicalTrials.gov |
Total clinical trials: 121
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AG-120 | Other | Phase PHASE2 | Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04278781 |
| Mitapivat-matching placebo | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05031780 |
| Mitapivat | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05031780 |
| Tebapivat Matched Placebo | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT06924970 |
| Tebapivat | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT06924970 |
| AG-120 | Other | Phase PHASE2 | Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04278781 |
| Mitapivat-matching placebo | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05031780 |
| Mitapivat | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05031780 |
| Tebapivat Matched Placebo | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT06924970 |
| Tebapivat | Other | Phase PHASE2 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT06924970 |
| Placebo and AIR001 Inhalation Solution (Expansion arm) | DRUG | Phase PHASE1 | Pulmonary Arterial Hypertension | COMPLETED | NCT00814645 |
| 25% MTD sodium nitrite inhalation solution | DRUG | Phase PHASE1 | Pulmonary Hypertension | COMPLETED | NCT01409122 |
| 120 mg sodium nitrite inhalation solution | DRUG | Phase PHASE1 | Pulmonary Hypertension | COMPLETED | NCT01409122 |
| 45 mg sodium nitrite inhalation solution | DRUG | Phase PHASE1 | Pulmonary Hypertension | COMPLETED | NCT01409122 |
| 90 mg sodium nitrite inhalation solution | DRUG | Phase PHASE1 | Pulmonary Hypertension | COMPLETED | NCT01409122 |
| 15 mg sodium nitrite inhalation solution | DRUG | Phase PHASE1 | Pulmonary Hypertension | COMPLETED | NCT01409122 |
| Ezetimibe | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00405067 |
| BMS-201038 (AEGR-733) | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00405067 |
| Gemfibrozil | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02230033 |
| JNJ-56021927 tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02031666 |
| JNJ-56021927 capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02031666 |
| Sodium Nitrite Inhalation Solution | DRUG | Phase PHASE1 | Pulmonary Arterial Hypertension | COMPLETED | NCT00814645 |
| Lomitapide | DRUG | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT01556906 |
| AEGR-733 and ezetimibe | DRUG | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00559962 |
| AEGR-733 and fenofibrate | DRUG | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00559962 |
| AEGR-733 and atorvastatin | DRUG | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00559962 |
| placebo | DRUG | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00559962 |
| AEGR-733 | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00690443 |
| Extended Release Niacin | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| dextromethorphan | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| fenofibrate | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| ezetimibe | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| simvastatin | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| atorvastatin | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT00359281 |
| EE/norgestimate | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02080468 |
| Nebulized Sodium Nitrite | DRUG | Phase PHASE2 | Heart Failure | COMPLETED | NCT02742129 |
| RAD1901 | DRUG | Phase PHASE2 | Hot Flashes | COMPLETED | NCT00875420 |
| [14]-AST2818 | DRUG | Phase PHASE1 | Healthy Male Volunteers | COMPLETED | NCT03941340 |
| AST2818 Tablets | DRUG | Phase PHASE1 | Healthy Male Volunteers | COMPLETED | NCT03926182 |
| Atorvastatin | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00690443 |
| lomitapide | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02044419 |
| LHRH Agonist | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01790126 |
| Furmonertinib (160mg) | DRUG | Phase PHASE2 | Non-Small-Cell Lung Cancer | UNKNOWN | NCT05255406 |
| RAD011 | DRUG | Phase PHASE3 | Prader-Willi Syndrome | WITHDRAWN | NCT05387798 |
| Anlotinib | DRUG | Phase PHASE2 | Non-Small-Cell Lung Cancer | UNKNOWN | NCT04895930 |
| JNJ-56021927 Tablet Formulation 3 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02160756 |
| JNJ-56021927 Tablet Formulation 2 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02160756 |
| JNJ-56021927 Tablet Formulation 1 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02160756 |
| JNJ-56021927 Softgel Capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02160756 |
| ARN-509 | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01790126 |
| Alflutinib | DRUG | Phase PHASE2 | Advanced NSCLC Patients With T790M | TERMINATED | NCT03452592 |
| Carboplatin | DRUG | Phase PHASE3 | Advanced Non-squamous Non-small-cell Lung Cancer | RECRUITING | NCT06416410 |
| Pemetrexed | DRUG | Phase PHASE3 | Advanced Non-squamous Non-small-cell Lung Cancer | RECRUITING | NCT06416410 |
| Tislelizumab | DRUG | Phase PHASE3 | Advanced Non-squamous Non-small-cell Lung Cancer | RECRUITING | NCT06416410 |
| Rifampicin | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06162169 |
| Midazolam , Rosuvastatin calcium and digoxin | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06162169 |
| [14C]JAB-21822 | DRUG | Phase PHASE1 | Mass Balance Study in Healthy Subjects | COMPLETED | NCT05920941 |
| Osimertinib | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04720976 |
| Sotorasib | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04720976 |
| Pembrolizumab | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04720976 |
| Binimetinib | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04720976 |
| Placebo AST2818 80mg//40 mg | DRUG | Phase PHASE3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03787992 |
| Gefitinib 250 mg | DRUG | Phase PHASE3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03787992 |
| Placebo Gefitinib 250 mg | DRUG | Phase PHASE3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03787992 |
| Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo | DRUG | Phase PHASE3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03787992 |
| [18F]RP-115 PET/MRI or PET/CT and MRI | DRUG | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT05374278 |
| JAB-3312 | DRUG | Phase PHASE3 | Advanced Non-squamous Non-small-cell Lung Cancer | RECRUITING | NCT06416410 |
| Furmonertinib | DRUG | Phase PHASE2 | Lung Adenocarcinoma | NOT_YET_RECRUITING | NCT04965831 |
| Furmonertinib 240mg | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT04858958 |
| Furmonertinib 160mg | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT04858958 |
| Metreleptin | DRUG | Phase PHASE4 | Generalized Lipodystrophy | COMPLETED | NCT04026178 |
| ADT (Standard of Care) | DRUG | Preclinical | Prostatic Neoplasms | NO_LONGER_AVAILABLE | NCT03523338 |
| ASTX727 | DRUG | Phase PHASE2 | Malignant Peripheral Nerve Sheath Tumors (MPNST) | RECRUITING | NCT04872543 |
| Osimertinib Mesylate Tablets | DRUG | Phase PHASE3 | NSCLC Patients With Brain Metastasis | RECRUITING | NCT06970639 |
| Furmonertinib Mesilate Tablets | DRUG | Phase PHASE3 | NSCLC Patients With Brain Metastasis | RECRUITING | NCT06970639 |
| Carboplatin Injection | DRUG | Phase PHASE3 | NSCLC Patients With Brain Metastasis | RECRUITING | NCT06970639 |
| Cisplatin for injection | DRUG | Phase PHASE3 | NSCLC Patients With Brain Metastasis | RECRUITING | NCT06970639 |
| Pemetrexed Disodium for Injection | DRUG | Phase PHASE3 | NSCLC Patients With Brain Metastasis | RECRUITING | NCT06970639 |
| Firmonertinib Mesilate Tablets | DRUG | Phase PHASE3 | EGFR | RECRUITING | NCT06956001 |
| AST2303 Tablets(ABK3376 Tablets) ，125mg | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT06955988 |
| AST2303 Tablets(ABK3376 Tablets) ，100mg | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT06955988 |
| AST2303 Tablets(ABK3376 Tablets) ，75mg | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT06955988 |
| AST2303 Tablets(ABK3376 Tablets) ，50mg | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT06955988 |
| AST2303 Tablets(ABK3376 Tablets) ，25mg | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT06955988 |
| ARN-509 (Phase 2) | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01171898 |
| ARN-509 (Phase 1) | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01171898 |
| Rosuvastatin | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | ACTIVE_NOT_RECRUITING | NCT02592317 |
| Pioglitazone | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | ACTIVE_NOT_RECRUITING | NCT02592317 |
| Drug Cocktail | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | ACTIVE_NOT_RECRUITING | NCT02592317 |
| JNJ 56021927 | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | ACTIVE_NOT_RECRUITING | NCT02592317 |
| JNJ-56021927 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02230033 |
| Abiraterone Acetate | DRUG | Phase PHASE1 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02123758 |
| Cetuximab | DRUG | Phase PHASE1 | Advanced Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05194995 |
| JAB-21822 | DRUG | Phase PHASE3 | Advanced Non-squamous Non-small-cell Lung Cancer | RECRUITING | NCT06416410 |
| Fusidic Acid 1% | DRUG | Phase PHASE3 | Bacterial Conjunctivitis | RECRUITING | NCT06911424 |
| 74-80 Grays (units of radiation) | RADIATION | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02531516 |
| GnRH (agonist) | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02531516 |
| Apalutamide Placebo | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02531516 |
| Bicalutamide Placebo | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02531516 |
| Bicalutamide | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02531516 |
| Androgen Deprivation Therapy (ADT) | DRUG | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02489318 |
| Prednisone | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01792687 |
| Abiraterone acetate | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01792687 |
| Apalutamide | DRUG | Phase PHASE1 | Castration-Resistant Prostate Cancer | COMPLETED | NCT02578797 |
| Mitapivat Matched Placebo | DRUG | Phase PHASE3 | Transfusion-dependent Alpha-Thalassemia | NOT_YET_RECRUITING | NCT07506863 |
| AG-236 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07075640 |
| Tebapivat Matched Placebo | DRUG | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06924970 |
| [13C2,15N3]-tebapivat | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06745271 |
| [14C]-tebapivat | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06745271 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06648824 |
| AG-181 | DRUG | Phase PHASE1 | Phenylketonuria | NOT_YET_RECRUITING | NCT07241234 |
| Tebapivat | DRUG | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06924970 |
| Mitapivat-matching placebo | DRUG | Phase PHASE3 | Pediatric Pyruvate Kinase Deficiency | ACTIVE_NOT_RECRUITING | NCT05175105 |
| Blood Draw | PROCEDURE | Preclinical | Pyruvate Kinase Deficiency | ACTIVE_NOT_RECRUITING | NCT04902833 |
| Placebo Matching Mitapivat | DRUG | Phase PHASE3 | Non-Transfusion-dependent Alpha-Thalassemia | NOT_YET_RECRUITING | NCT07517133 |
| Mitapivat tablet | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04696393 |
| Mitapivat coated granules | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04565678 |
| Mitapivat tablets | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04565678 |
| AG-946 Matched Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04536792 |
| AG-946 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04536792 |
| Placebo for Treatment C | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04472832 |
| Mitapivat 300 mg | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04472832 |
| Placebo for Treatment B | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04472832 |
| Mitapivat 100 mg | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04472832 |
| Placebo for Treatment A | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04472832 |
| AG-120 | DRUG | Phase PHASE2 | Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04278781 |
| Omeprazole | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06162169 |
| AG881 Formulation 2 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04128787 |
| AG881 Formulation 1 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04128787 |
| ivosidenib and nivolumab | DRUG | Phase PHASE2 | Advanced Solid Tumor | COMPLETED | NCT04056910 |
| Lamotrigine | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04015687 |
| mitapivat sulfate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03991312 |
| rifampin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03991312 |
| itraconazole | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03991312 |
| [13C315N3]AG-881 | DRUG | Phase PHASE1 | Healthy Male Participants | COMPLETED | NCT03960502 |
| AG-881 | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04015687 |
| Mitapivat | DRUG | Phase PHASE3 | Non-Transfusion-dependent Alpha-Thalassemia | NOT_YET_RECRUITING | NCT07517133 |
| AG-636 | DRUG | Phase PHASE1 | Lymphoma | TERMINATED | NCT03834584 |
| [13C6]AG-348 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03703505 |
| Ivosidenib | DRUG | Phase PHASE1 | IDH1 Mutation Myeloid Neoplasms | COMPLETED | NCT03564821 |
| AG-348 Sequence B | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03397329 |
| AG-348 Sequence A | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03397329 |
| AG-120 (Ivosidenib) | DRUG | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03282513 |
| ivosidenib (AG-120) | DRUG | Preclinical | Acute Myeloid Leukemia | APPROVED_FOR_MARKETING | NCT03245424 |
| Itraconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02230033 |
| AG-519 | DRUG | Phase PHASE1 | Anemia | TERMINATED | NCT02630927 |
| AG120 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02831972 |
| AG881 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04145128 |
| [14C]-AG-120 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02489513 |
| AG221 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218346 |
| Placebo | OTHER | Phase PHASE2 | Heart Failure | COMPLETED | NCT02262078 |
| AG-348 | DRUG | Phase EARLY_PHASE1 | Sickle Cell Disease | COMPLETED | NCT04000165 |
| Enasidenib | DRUG | Phase PHASE1 | Hematologic Neoplasms | COMPLETED | NCT01915498 |
Total products: 153